No Data
Express News | Contineum Therapeutics Inc - Expects $213.9 Mln Cash to Fund Operations Through 2027
Express News | Contineum Therapeutics Inc - Phase 1B Study for Pipe-791 to Begin in Q1 2025
Express News | Contineum Therapeutics Inc: Phase 1B Study for Potential Treatment of Osteoarthritis and Low Back Pain Expected to Commence in Q1 of 2025
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
Express News | Contineum Therapeutics Expands Clinical Development of Pipe-791 With FDA Authorization of Its Investigational New Drug (Ind) Application for Chronic Pain
Here's Why We're Not At All Concerned With Contineum Therapeutics' (NASDAQ:CTNM) Cash Burn Situation
No Data
No Data